Function and evolution of RNA N6-methyladenosine modification

Zhi-Man Zhu*, Fu-Chun Huo*, Dong-Sheng Pei†

Department of Pathology, Xuzhou Medical University, Xuzhou 221004, China

*These authors contributed equally to this work.
†Corresponding author: Dong-Sheng Pei, Address: 84 West Huaihai Road, Xuzhou, Jiangsu, P. R. China. E-mail: dspei@xzhmu.edu.cn

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.02.23; Accepted: 2020.04.05; Published: 2020.04.15

Abstract

N6-methyladenosine (m6A) is identified as the most prevalent and abundant internal RNA modification, especially within eukaryotic mRNAs, which has attracted much attention in recent years since its importance for regulating gene expression and deciding cell fate. m6A modification is installed by RNA methyltransferases METTL3, METTL14 and WTAP (Writers), removed by the demethylases FTO and ALKBH5 (Erasers) and recognized by m6A binding proteins, such as YT521-B homology YTH domain-containing proteins (Readers). Accumulating evidence shows that m6A RNA methylation participates in almost all aspects of RNA processing, implying an association with important bioprocesses. In this review, we mainly summarize and discuss the functional relevance and importance of m6A modification in cellular processes.

Key words: m6A modification, methylation, RNA, function

Introduction

To date >170 chemical modifications in RNA have been found in organisms [1]. N6-methyladenosine (m6A) modification was firstly discovered in the early 1970s from cancer cells. This modification also exists in various species, including yeast, Arabidopsis, Drosophila, various viruses, zebrafish, plants, fruit flies, mice, and humans [2]. In 2012, Dominissini et al. revealed the m6A distribution in human and mouse and identified more than 12000 methylated sites on human mRNAs by utilizing m6A-seq [3]. m6A sites are highly conserved and generally enriched in the consensus motif RRACH (R = G or A and H = A, C, or U), which is more prone to be detected in the 3’-untranslated regions (3’UTRs), near stop codons and within internal long exons [3].

m6A methylation is introduced into RNAs by a multicomponent methyltransferase complex (m6A writers). The complex traditionally consists of methyltransferase-like 3 (METTL3), METTL14 and Wilms’ tumor 1-associating protein (WTAP), which effectuates the m6A methylated group into RNAs. Subsequently, new writers, such as RBM15(B), HAKAI, METTL16, KIAA1429 (VIRMA) and ZC3H13 have been identified [1, 4]. METTL3 serving as the core component and METTL14 recognizing target RNAs integrate a stable heterodimer complexes referring to interacting with other m6A cofactors to synergistically catalyze m6A methylation [5]. WTAP contributes to the methyltransferase complexes anchoring in nuclear speckles. m6A methylation can be removed by RNA demethylases (m6A erasers), fat mass and obesity-associated protein (FTO) and AlkB family member 5 (ALKBH5). FTO, the first identified m6A demethylase, oxidizes m6A in RNA to N6-hydroxymethyladenosine and N6-formyladenosine [6]. ALKBH5, an FTO homologue, directly abrogates m6A modification to adenosine without intermediate detected [7]. Although the m6A modification is dynamically regulated by writers and erasers, the proteins (m6A readers) preferentially recognizes m6A-modified sites, influencing RNA fate and endowing distinct biological functions. m6A readers, mainly including YT521-B homology (YTH) domain family proteins (YTHDF1~3), YTH domain containing...
proteins (YTHDC1~2), IGF2BP1~3, HNRNPC/G/A2B1 and eIF3, regulate RNA processing, structure, nuclear export, translation and degradation. YTH domain, as m^6^A binding module, shares a conserved α/β fold and can discriminate between non-modified and m^6^A mRNAAs [8, 9]. YTHDF1 can bind to the 3'UTRs and stop codon of m^6^A-containing RNA and promotes translation initiation by interacting with eIF3 [10]. Binding sites of YTHDF3 also primarily locates in 3'UTR [11]. YTHDF2 associates with half-life of mRNA. YTHDC1 regulates transcription of target genes and alternative splicing of mRNA [12]. HNRNPC regulates mRNA structure, while HNRNPA2/B1 involves pre-miRNA transcription [13]. IGF2BP3 enhances mRNA stability and storage. Reader proteins combine m^6^A methylation with RNA processing and biological functions.

m^6^A modification characterized by wide existence, unique distribution and dynamic reversibility. m^6^A methylation regulatory network regulates RNA processing and metabolism and participate in many cellular biological processes, such as immune modulation, fat metabolism, biological rhythm, reproductive development, and its disorders can cause various diseases. In this review, we summarized the current knowledge on the function and biology of m^6^A methylation.

Detection of m^6^A methylation

Due to technical bottlenecks, it makes the m^6^A methylation more mysterious and incomprehensible. m^6^A modification neither modulates reverse transcription nor is analogous to m^7^G methylation characterized by wide existence, unique distribution and dynamic reversibility. m^6^A methylation regulatory network regulates RNA processing and metabolism and participate in many cellular biological processes, such as immune modulation, fat metabolism, biological rhythm, reproductive development, and its disorders can cause various diseases. In this review, we summarized the current knowledge on the function and biology of m^6^A methylation.

Detection of m^6^A methylation

Due to technical bottlenecks, it makes the m^6^A methylation more mysterious and incomprehensible. m^6^A modification neither modulates reverse transcription nor is analogous to m^7^G methylation characterized by being specifically cleaved, the presence of m^6^A and differential pattern at a particular mRNA is challenging to observe and detect [14, 15]. m^6^A methylation has not been characterized until the availability of transcriptome-wide mapping approaches, m^6^A-seq and MeRIP-seq [3, 15, 16], both of which capture m^6^A RNA fragments through immunoprecipitation and then identify modified sequences.

Based on the theory, researchers detect an enormous amount of highly conserved m^6^A sites and also determine over 12,000 m^6^A signal peaks on 7,676 mammalian genes [3, 17]. Nevertheless, the above detection analysis is insufficient to discriminate two adjacent m^6^A sites, and m^6^A mapping methods localize m^6^A residues to about 100–200 nucleotides, which may not accurately identify m^6^A sites in a whole transcript [18]. Besides, both m^6^A-seq and MeRIP-seq may misread m^6^A modification that occurs at the 3'UTR ends of mRNA and is analogous to m^6^A modification containing the sixth methyl group as m^6^A methylation. MeRIP-Seq can identify m^6^A-modified sites in mammalian cells, whereas the way which is complex and only separate the m^6^A-abundant regions. Considering the above defects, researchers have made improvements in detection techniques for m^6^A methylation site. Ultraviolet cross-linking immunoprecipitation technology, including miCLIP [19], PA-m^6^A-seq [20], m^6^A-CLIP (also called UV-CLIP) [14, 21], are reported to overcome the defects above, which could discriminate m^6^A methylation at an individual-nucleotide resolution more accurately and provide higher resolution transcriptome-wide maps of m^6^A methylation. Another technique, m^6^A-LAIC-seq, introducts spike-in RNA as an internal reference founded upon m^6^A-seq and then calculates the methylation level of m^6^A modification at each gene fragment in a full transcriptome, however, it is incapable of determining single-base resolution of m^6^A modification [22].

In addition to high-throughput sequencing, monitoring of the m^6^A modification at an exact position of mRNA is also very essential. SCARLET, as the most common strategy, accurately maps a single m^6^A site in both IncRNAs and mRNAs and then determine the m^6^A methylation content in total RNA [23, 24]. Albeit SCARLET with low-throughput and fancy features, the feasibility and accuracy allow SCARLET to be a frequently-used strategy for examining the accuracy of high-throughput detection of m^6^A modification. And SCARLET can also be allowed to screen other types of epigenetic modifications in RNA, such as m^5^C and Ψ modifications [25]. Golovina et al. reported a strategy based on high-resolution melting analysis for monitoring m^6^A sites in a specific RNA position [26]. Mechanistically, m^6^A methylation alters the melting temperature, which is indirectly measured by qPCR [26]; however, whether it can be popularized remains to be verified. The recently proposed m^6^A-REF-seq provides a novel perspective for the identification of m^6^A single site, which eliminates the requirement for m^6^A specific antibody and makes it more suitable for the detection of minute and precious samples [27]. In recent years, new auxiliary detection technologies continue to emerge, which further improve the accuracy, sensitivity and application range of the traditional high-throughput sequencing. The improvement of detection strategies contributes to profoundly comprehend the m^6^A modification and its associations with various pathophysiologys.

Prediction of m^6^A methylation (site)

Since the identification of m^6^A methylation requires plenty of workforce and material resources, and it is rather dynamic and tissue-specific,
bioinformatics prediction greatly improving research efficiency for the distribution and pattern of m^6A methylation is developed. Zhang et al. firstly proposes the HIDDEN MARKOV MODEL to predict residual sites around known sites [28]. Subsequently, pRNAm-PC and iRNA-Methyl (http://lin.uestc.edu.cn/server/iRNA-Methyl) for predicting m^6A sites are developed, and the common characteristics of both are the application of support vector machine model [29, 30]. According to this philosophy, Jia et al. develop RNA-methylPred method, a highly accurate predictor for identifying m^6A sites, which is more efficient than before [31]. Li et al. propose a better TargetM6A method, which can only predict the m^6A sites in pri-miRNAs(http://csbio.njust.edu.cn/bioinf/TargetM6A) [32]. Zhou et al. synthesize a variety of mathematical models and reports SRAMP predictor that is more effectively to predict m^6A sites in mammalian RNAs [29]. In 2018, a database website named RMBaseV2.0 was established, and it includes sequencing data of multiple epigenetic modifications of RNAs in 13 species (http://rna.sysu.edu.cn/rmbase/), including mass data on m^6A methylation sites [33].

**Biological functions of m^6A modification**

m^6A functional enzymes cooperatively effectuates the dynamic balance of intracellular regulatory network m^6A modification. Formidable evidence has revealed the important roles of m^6A modification in various biological functions (Figure 1 and 2), such as RNA metabolism, adipogenesis (Figure 3), spermatogenesis, circadian rhythm, immune response, stem cell maintenance and tumorigenicity (Figure 4). Next, we mainly introduce several relatively well-studied roles of m^6A modification in pathophysiological process.

**m^6A in mRNA metabolism**

The interaction between m^6A modification and its regulators reconstructs dynamic regulatory networks, which is responsible for the mRNA processing and metabolism (Figure 1), from mRNA transcription, splicing and export in the nucleus to translation, localization and degradation in the cytoplasm, and further influencing gene expression, leading to various pathophysiologic processes.

**m^6A and mRNA splicing**

The process of pre-mRNA maturating into mRNA consists of 5' capping, 3' polyadenylation and splicing. Pre-mRNA splicing responsible for precise intron excision and exon connection is a necessary procedure for gene expression and enriches the diversity of gene products. m^6A modification was initially considered as a splicing regulator, and prior research has revealed that it is more abundant in pre-mRNA than in mature mRNA [34]. m^6A modification is frequently enriched in the intron region of pre-mRNA [35, 36], its regulators primarily locate in nucleus speckle, a well-known location of pre-mRNA processing [37], and little methylation or demethylation occurs in cytoplasmic mRNA [38]. Therefore, it can be inferred that m^6A modification responsible for mRNA splicing occurs in the nucleus. Different effects of mRNA splicing accompany knockout of WTAP or
METTL3, and WTAP is a known splicing factor [39]. Inhibiting WTAP impairs mRNA levels and leads to abnormally alternative splicing of mRNA. METTL3 causes mis-splicing and instability of the mRNA [40]. FTO silencing potentiates the splicing ability of SRSF2 and augments the number of target exons [41, 42]. In addition, ALKBH5 has also been proved to affect splicing rates of mRNA [7]. YTHDC1 can bind with SRSF3 and promote pre-mRNA splicing to mature mRNA [37]. HNRNPC and HNRNPG are also responsible for pre-mRNA processing and mRNA maturation [43, 44]. Remarkably, Ke et al. reported that m^6^A modification is not completely essential for the most mRNA splicing but acts as a determinant of cytoplasmic mRNA stability [38]. Recently, it has been reported that m^6^A-Assisted polyadenylation signals protect transcriptome integrity via exhibiting chimera formation in Arabidopsis thaliana RNA [45].

**m^6^A and mRNA localization**

Nuclear export of mRNA is quite an important process to connect mRNA transcription and processing in nucleus with gene expression in cytoplasm. m^6^A modification contributes to nuclear export of mRNA, and attenuation of METTL3 reverses m^6^A modification and then jeopardizes the mRNA export [46]. ALKBH5 depletion accelerates the mRNA translocation from the nucleus to the cytoplasm [7], whereas ectopic expression of ALKBH5 causes nuclear retention of mRNA of antiviral transcripts, thereby inhibiting transcription of mRNA transcripts [47]. YTHDC1 recognizes m^6^A-modified mRNA and promotes its combining with nuclear RNA export factor NXF1 and transport adaptor SRSF3 to promote nuclear export [48].

**m^6^A and mRNA translation**

METTL3 regulates mRNA translation through a different mechanism. By interacting with eIF3h, METTL3 promotes formation of densely packed polyribosomes and enhances translation of target mRNAs independently of its catalytic activity and m^6^A readers [48, 49]. Stated differently, METTL3 localizing to the transcriptional start site frequently accompanied by CAATT-box binding protein CEBPZ of downstream genes induces m^6^A mRNA modification and augments translation via alleviating ribosome stalling [50]. Through interacting ribosome and initiation factor, YTHDF1 binds to m^6^A-containing mRNAs and drives translation in an m^6^A-dependent manner [10, 51]. On the other hand, YTHDF3 can also promote translation efficiency by combining with YTHDF1 and eIF4A3 [52], indicating that YTHDF3 and YTHDF1 cooperate in the process of mRNA translation [53]. Besides, IGF2BP1/2/3 can also accelerate mRNA translation [54].

**m^6^A and mRNA degradation**

Reversing m^6^A with the blockade of METTL3 or METTL14 alleviates degradation efficiency of mRNA and enhances gene expression [55]. ALKBH5 regulates the stability of CYR61 mRNA and elevates its expression in trophoblast, which is deciphered by the mechanism that silenced ALKBH5 enhances the half-life of CYR61 mRNA [56]. YTH domain in C-terminal of YTHDF2 binds to m^6^A-containing mRNA, while domains in N-terminal locate the mRNA to “RNA degrader” for further degradation [57]. Recent studies reported that YTHDF2 destabilizes modified mRNA mainly by two distinct
pathways, YTHDF2-CCR4/NOT complex and YTHDF2-HRSP12-RNase P/MRP complex [58]. And YTHDF2-HRSP12-RNase P/MRP is also scalable for m6A-modified circRNA [58]. HuR binds to the U-enriched region of 3’UTR of mRNA and jeopardizes the interaction the binding of mRNA to the Ago complex, preventing mRNA degradation [59]. m6A modification impairs the binding ability of HuR and destabilizes m6A-containing transcripts. Similarly, blockade of METTL3 impedes the interaction between Ago2 and target mRNA, enhancing mRNA stability [10]. What is of noteworthiness is that IGF2BP-mediated m6A “Reading” recently has been reported the promotive effect on mRNA stability, and IGF2BP may combine with mRNA-stabilizing proteins, such as HuR, MATR3 and PABPC1 to elevate the mRNA stability [52]. In conclusion, m6A modification can regulate gene expression through modulating mRNA stability and degradation.

m6A and mRNA structure

m6A modification can alter the mRNA structure and make it prone to combine with HNRNPC and HNRNPG. m6A methylation contributes unwind partial mRNA double-strand of MALAT1 and CDS2 to exposure single-stranded U sites, and HNRNPC can recognize specific sites to regulate gene expression [13]. m6A methylation of MALAT1 hairpin strengthens accessibility of HNRNPG binding by its C-terminal low-complexity region rather than the conventional RNA binding domain [60]. The effect of structural remodeling partly caused by m6A modification on the binding of mRNA to proteins is called “m6A switch”, which is ubiquitous in the transcriptome, and plays biological function by regulating the interaction between mRNAs and binding proteins [13].

m6A in adipogenesis and obesity

Early studies revealed that ectopic expression of FTO enhances food intake and fat mass in mice [61], while blockade of FTO protects against fat accumulation [62, 63]. FTO has been identified as a positive and essential regulator of preadipocyte differentiation [64-66]. And accumulating evidence highlights the necessity for FTO/m6A/YTHDF2 axis in adipogenesis regulation [64, 65]. FTO silencing accelerates the decay of JAK2 mRNA in an m6A-YTHDF2 dependent mechanism, which restricts STAT3 phosphorylation and C/EBPβ transcription and expression, suppressing adipogenesis, and treating with specific FTO inhibitor also eliminates the accumulation of lipid droplets [67]. Loss of FTO impedes adipogenesis of 3T3-L1 preadipocyte via the prolongation of cell cycle progression in which YTHDF2 recognizes and destabilizes m6A-modified CCNA2 and CDK2 mRNAs, crucial cell cycle regulator [64]. Consistent with this, epigallocatechin gallate, as upstream regulators, negatively regulates FTO/m6A/YTHDF2 axis and induces adipogenesis inhibition in 3T3-L1 preadipocyte [65]. The latest research indicated that METTL3 knockdown decreases m6A mRNA modification of JAK1, rather than JAK2, and impairs YTHDF2-mediated mRNA degradation, which activates JAK1/STAT5/C/EBPβ pathway and expedites adipogenesis of bone marrow stem cells in porcine [68]. ZFP217 directly activates the FTO transcription by binding to its promoter and interacts with YTHDF2 to maintain FTO-induced m6A demethylation, thereby facilitating adipogenesis of 3T3-L1 cells [66]. m6A methylation expedites adipogenesis of intramuscular preadipocyte through enhancing

Figure 4. Mechanisms of m6A modification in various human cancers.
MTCH2 expression in a YTHDF1-dependent mRNA translation [69]. Besides, m^6^A participates in heat stress-associated lipid metabolism, and its regulators including METTL14, WTAP, FTO, and YTHDF2 and m^6^A levels are increased in the liver and abdominal fat of neonatal piglets following heat stress exposure [70]. In summary, m^6^A modification and its modulators, especially FTO, functionally regulate adipogenesis (Figure 3), which provides a new understanding for pathogenesis and treatment of obesity-associated diseases from the RNA epitranscriptome modification.

m^6^A in embryonic development and sex determination

m^6^A modification can regulate the mRNA process in the initial stage of life, and its aberrant alterations will inevitably cause abnormal embryonic development. Abnormal m^6^A modification affects the formation of male and female gametes, or restricts the activation of zygote genes, leading to abnormal embryonic development, and influence the normal function of offspring.

METTL3 modulates the alternative splicing of spermatogenesis-related genes, which are responsible for male fertility and spermatogenesis, and deletion of which influences spermatogonial differentiation and hinders meiosis initiation in mice [40]. In Saccharomyces cerevisiae, the knockdown of IME4, a homologous gene of METTL3, causes sporulation defects [71]. In Arabidopsis thaliana, the inactivation of MTA, a homologous gene of METTL3, causes the formation of lethal phenotypes or the stagnation of seed development in the spherical phase [72]. Analogously, in Drosophila melanogaster, IME4, is critical for the regulation of Notch signaling in follicular development [73]. Furthermore, IME4 regulates meiotic DNA replication and promotes meiosis in yeast through downregulating RME1 (a transcriptional repressor of meiosis) mRNA levels in an m^6^A-dependent manner [74]. Upon METTL3 knockdown in the immature embryonic stem cells of mice, the immature phenotype cannot be fully terminated because of the inability of m^6^A modification, leading to early embryonic death [75].

The expression of ALKBH5 in mouse testis is considerably higher than that in other tissues. ALKBH5 silencing in mice results in testicular atrophy, lighter weight, reduced sperm quantity and quality and also causes reproductive dysfunction, such as apoptosis and fertility decline. Drosophila melanogaster lacking m^6^A modification induces fly failure and fertility decline, accompanied by the deficiencies in nerve, sex determination and dose compensation [73, 76]. ALKBH5 amplification in testis is indispensable for the correct splicing of long 3′UTR of mRNA in spermatocytes, which is involved in spermatogenesis and mouse reproduction [7, 77]. Inhibiting ALKBH5 results in aberrant splicing and shorter transcripts of mRNAs, ultimately developing meiosis abnormality of spermatocytes and male infertility in mice [77, 78]. Meclofenamic acid suppresses cell viability and blocks G1/S progression in spermatogonia of mice through accelerating the degradation of CDK2 mRNA via specifically decreasing FTO and elevating the m^6^A content of 3′UTR [79].

YTHDF2-mediated mRNA degradation exerts essential functions in sexual reproduction of mammalian [80, 81]. YTHDF2 deletion in an embryo of zebrafish decelerates the degradation of m^6^A-modified maternal transcripts and impedes the activation of zygote genome, which prevents the maternal-to-zygotic transition, thereby delaying the development of zebrafish larvae [82]. YTHDF2 acts as an intrinsic determinant for early zygotic development and mammalian egg quality [81]. Due to the failure of regulating the transcription of genes involved in oocyte maturation, female mice with YTHDF2 knockout are deprived of fertility [81]. YTHDC1 is essential for oocyte growth and maturation in female mice and spermatogonia survival in male mice, and m^6^A methylation can compromise the alternative splicing defects caused by YTHDC1 silencing in mouse oocytes [37]. In the testis of wild male mice, YTHDC2 expression is up-regulated at the beginning of meiosis, while in the testis with YTHDC2 knockout, healthy sperm could not be produced [82].

m^6^A in virus replication and infection

m^6^A methylation not only works a crucial role in host cells; but also in diverse viral RNAs. It was initially described in IAV and adenovirus [83, 84]. Subsequently, it was discovered in HSV-1, KSHV, Rous sarcoma virus, avian sarcoma virus B77, feline leukemia virus, HIV-1, Zika virus (ZIKV), simian virus 40 (SV40), HBV, HCV, flavivirus and plant virus (alfalfa mosaic and cucumber mosaic virus) [85-89]. m^6^A modification may present an entirely opposite pattern in the replication of different viruses. Mechanism dissection revealed that m^6^A methylation regulates virus replication and infection, which are mainly achieved by affecting the stability of virus mRNAs or genomic RNAs. And m^6^A modification in host-viral interactions is indispensable for modulating virus replication and infection [87, 90, 91].

The translation of HIV-1 mRNA is dominated by cap-dependent and independent manners [92], and the m^6^A modification in stem-loop II region of HIV-1
Rev response element (RRE) contributes to HIV-1 Rev protein binding to RRE, thereby affecting nuclear export of HIV-1 mRNA [86]. Accumulating studies have identified the specific sites of m^6^A and methylation peaks in HIV-1 mRNAs [86, 93-95], all of which suggests that m^6^A modification performs a significant role in the HIV-1 genome. Altering m^6^A regulators, METTL3, METTL14, FTO and ALKBH5, affect HIV-1 related protein expressions, such as GP120, p24, p55 Gag [93], p24 and Nef are down-regulated expression in CD4+ T cells infected with HIV-1 after CRISPR-Cas-mediated deletion of YTHDF2 [87], HIV-1 infection is also amplified following the knockout of reader protein DF1-3 [93]. On the contrary, the enforced expression of these m^6^A readers inhibits HIV-1 replication and decrease Gag protein level. Drugs targeting m^6^A modification can be used as the development direction of antiviral drugs, such as 3-deazaadenosine (3-DAA), which has been shown to block the hydrolysis of S-Adenosylhomocysteine to degrade SAM, thus inhibiting the addition of m^6^A group to the mRNA substrate. Kennedy et al. treated HIV-1-infected CEM-SS cells with 3-DAA and found that the replication of HIV-1 is deprived, which proves the inhibitory effect of 3-DAA on HIV-1 replication [95]. The 3-DAA, too, has an excellent inhibitory effect on the replication of RSV, IAV and other viruses [96, 97].

m^6^A writers and erasers are found to shuttle to the cytoplasm to modulate the m^6^A methylation of flavivirus RNAs [98, 99], and m^6^A modification regulates the virus-like particle production and the infections of HCV and ZIKV [98, 99]. m^6^A methylation enriched in the KSHV genome might regulate alternative splicing of the ORF50 pre-mRNA and control governing switch of KSHV replication [85, 100]. And knockdown of METTL3 abrogates the expression of KSHV lytic genes and halts virus production [85]. m^6^A methylation accelerates SV40 replication by potentiating the translation and export of viral transcripts [101]. HBV related HBs and Hbc proteins increases followed by METTL3 or METTL14 silencing; on the contrary, inhibiting FTO or ALKBH5 enforces their expression [87, 102]. m^6^A methylation participates in the regulation of HBV life cycle via affecting transcript stability [87, 102]. The lower m^6^A modification makes some viruses successfully evade the immune surveillance, so whether there is some mechanism that can detect these abnormal methylations and then feedback to the immune system for treatment, which needs further study.

m^6^A in stress response

Following the heat shock, METTL3 locates in chromatin of the heat shock gene and catalyze m^6^A methylation. Nuclear YTHDF2 competes with FTO to prevent the reversal of m^6^A modification, thereby enhancing mRNA translation in a cap-dependent manner and improving the formation of related proteins [103]. YTHDF1 is responsible for confining stress particles induced by protein-encapsulated mRNAs and protein particles to the nucleus, somehow abrogating protein release and mRNA expression [103]. When the stress source disappears, the stress particles are re-depolymerized and released, and then encapsulated mRNAs re-express [103], which contributes to avoid the inflammation occurrence induced by stress sources whenever possible and is feasible and beneficial for injury repair. Similarly, due to be subjected to UV damage to DNA, METTL3-catalyzed m^6^A is quickly located at the injury site, and DNA polymerase κ is also recruited to ameliorate injury repair [104]. Recent research has demonstrated that multivalent m^6^A motifs enhances phase separation of YTHDF1/2/3 proteins through juxtaposing low-complexity domain of YTHDFs, which causes the presence of phase-separated compartments, such as P-body, neuronal RNA and stress granules [105, 106].

m^6^A in immune response

By regulating the IL-7/STAT5/SOCS pathway, m^6^A methylation affects T cell state, while the absence of METTL3 can destroy the homeostasis and differentiation of T cells [107]. Blockade of METTL3 in immature T cells augments the expression of SOCS1, SOCS3 and CISH, which inhibit the activation STAT5 mediated by IL-7 and the proliferation and differentiation of T cells [107]. Due to the loss of differentiation ability in METTL3-deficient T cells, it is insufficient to induce autoimmune diseases [107]. After virus infection, DDX46 recruits ALKBH5 to erase m^6^A modification of antiviral transcripts, resulting in the inability of antiviral transcripts translating into IFN-I and the failure of initiating natural antiviral immune responses [47]. m^6^A modification also participates in tumor antigen-specific immune response through modulating the translation efficiency of lysosome cathepsin in dendritic cells [108]. Knockout of YTHDF1 in mice can enhance the immune response of CD8+ T cells [108]. These findings are expected to provide innovative ideas for the treatment of autoimmune diseases and understanding the molecular mechanism of innate immunity in various diseases, especially virus infection [109].

m^6^A in differentiation of stem cells

m^6^A methylation is involved in regulating the fate-determining process of stem cells [75, 110]. m^6^A
modification maintains the balance of gene expression between endothelial cells and hematopoietic cells during endothelial-hematopoietic transformation by regulating Notch1a mRNA stability via YTHDF2, which then affects the fate of hematopoietic stem cells [111]. Reversing m6A modification treated with METTL3 or METTL14 blockade contributes to the amplification of transcription factors maintaining cell pluripotency and inhibits the self-renewal of embryonic stem cells [112, 113]. METTL3 knockout interferes with differentiation and self-renewal of mouse embryonic stem cells via decreasing m6A methylation of NANOG, leading to embryonic death [75]. However, ZC3H13 depletion impairs self-renewal of mouse embryonic stem cells due to the cells cultured in metastable naïve condition [114]. METTL3 depletion potentiates both calcium deposition and alkaline phosphatase activity of mesenchymal stem cells by modulating the expression of MYD required for activating NF-κB, as a repressor of osteogenesis, which uncovers the inhibitory role of METTL3 in osteogenic differentiation [115]. ALKBH5 deteriorates the m6A modification of NANOG mRNA to promote its expression in breast cancer stem cells following exposure to hypoxia, which furtherly accelerates cell proliferation and regulates cell differentiation [116]. It has further been proved that FTO stimulates the transformation of normal hematopoietic stem cells to pathological cells in leukemia [117], and can influence the selective splicing of key genes related adipogenesis, thereby affecting the preadipocyte differentiation [41]. In conclusion, m6A methylation plays a key role in regulating the differentiation and development of stem cells.

**m6A in nervous system**

Brain is one of the organs with the most abundant of m6A modification [118, 119]. m6A regulatory proteins are implicated in the cerebral cortex and synaptic function, axonal regeneration, self-renewal of neural stem cells and cerebellar development [118-122]. m6A methylation effectuates the region-specific gene regulation in the mouse brain [118]. Knockdown of METTL14 in the central nervous system of mice affect the development of cerebral cortex [120], METTL3 silencing seriously affects the development of cerebral cortex and cerebellum, leading to obvious motor dysfunction, even death during lactation [123]. Mechanically, m6A modification modulates the stability of transcripts associated with cerebellar development and affects pre-mRNA splicing in synapse [123].

Subsequent studies showed that m6A enrichment in the prefrontal lobe of mice contributes to learning training, implying the underlying mechanisms of m6A methylation in spatial learning and memory [121]. Suckling mouse with METTL3 knockout in the cortex and hippocampus displays a significant decline in learning ability [124]. In YTHDF1 knockout mice, hippocampus-dependent learning and memory dysfunction occurs, and the function and plasticity of excitatory synapses in hippocampal neurons are also impaired; on the contrary, forced expression of YTHDF1 ameliorates the injury [125]. The crucial role of m6A modification lays a foundation for further exploring the pathophysiology of memory formation.

**m6A in cancer**

Recently, emerging evidence has revealed that there are disorders of m6A components and abnormal modification of m6A in many types of cancers (Figure 4), which leads to the inactivation or overexpression of downstream carcinogenic or tumor suppressor genes and plays an important role in oncogenic transformation and tumor progression. It is worth noting that the same components in different types of tumors, or different components in the same tumor do not play the same role, or even the opposite.

m6A modification of mRNAs is significantly up-regulated during epithelial-mesenchymal transition, and it can regulate the genes related to invasion, metastasis and cell adhesion [126]. Through database analysis, it is found that FTO can regulate EGFR-related pathways and angiogenic signals, and overexpression of FTO inhibits tumor growth in vivo [127]. In tumor cells, METTL14 and ALKBH5 may play a cancer-promoting role by regulating the expression of angiogenesis-related genes such as TGF-β [128]. METTL3 or METTL14 depletion could induce the expression of ADAM19, EPHA3 and KLF4 mRNAs and promote the growth, self-renewal and tumorigenesis of glioblastoma stem cells [128]. Hypoxia stimulation-induced ALKBH5 abrogates the m6A methylation of NANOG mRNAs and enhances the mRNA stability, which in turn promotes the maintenance and metastasis of breast tumor stem cells [116]. In breast cancer, targeted inhibition of FTO can reduce the production of lactic acid and ATP and inhibit the activities of pyruvate kinase and hexokinase, and lead to the inactivation of AKT, overexpression of FTO can promote the glycolysis ability of tumor cells and the activation of PI3K/AKT pathway [129]. m6A modification activates Wnt/β-catenin pathway by stabilizing FZD10, which promotes BRAC deficiency and induce PARP inhibitor resistance of epithelial ovarian cancer cells [130]. Blockade of METTL3 can significantly increase the sensitivity of pancreatic cancer cells to anticancer
drugs 5-fluorouracil, cisplatin and radiotherapy [51]. In addition, R-2-hydroxyglutarate (R-2HG) can obviate FTO activity, which augments the m^6^A modification in R-2HG-sensitive leukemic cells, and then reduce the stability of MYC/CEBPA transcripts, promoting cell cycle arrest and apoptosis [131]. m^6^A modification is implicated in various aspects of multiple malignancies via regulating differentiation, proliferation, apoptosis, invasion, migration, angiogenesis, energy metabolism, autophagy and chemoradiotherapy resistance. Uncovering the underlying mechanism of m^6^A modification in initiation and progression of cancer extends opportunities for molecular pathological diagnosis and therapy strategies in cancer.

**m^6^A in heart**

Enhanced METTL3 induce cardiomyocyte hypertrophy without additional stimulation, and inhibition of METTL3 can effectively block the occurrence of hypertrophy *in vitro* [132, 133]. m^6^A methylation can expedite adaptive growth of cardiomyocytes and induce spontaneous cardiomyocyte remodeling [132, 133]. Studies have found that FTO is associated with various heart defects, including hypertrophic cardiomyopathy and interventricular remodeling [132, 133]. m^6^A occurrence of hypertrophy and arrhythmias and coronary heart disease [134]. Knockdown of FTO can cause the disorder of calcium homeostasis and sarcomere dynamics in heart failure and hypoxic cardiomyocytes and decrease the contractile function of cardiomyocytes [135].

**Conclusions**

The milestone in the study of RNA epigenetics was discovered in 2011 by He et al, who discovered the first m^6^A demethylase FTO, which reveals that m^6^A modification is dynamic and reversible, and enriches the post-transcriptional modification function of RNA and generates refueled passion in m^6^A research. In this review, m^6^A enzymes and its regulation on RNA processing and metabolism, various biological processes as well as in pathogenesis have been revealed. m^6^A modification can functionally regulate the transcriptome of eukaryotes, such as mRNA splicing, nucleation, localization, translation and stabilization and play crucial roles in various biological processes, such as stem cell differentiation, T cell homeostasis, brain development, biological rhythm, spermatogenesis, as well as the occurrence of a variety of diseases, including tumor, obesity and infertility. Therefore, it is particularly important to study the dynamic modification of m^6^A and the specific molecular mechanism of how it affects the biological function of cells.

However, the other components of m^6^A methyltransferase complex are not clear, the tissue-specific demethylase remains to be explored, and the binding proteins mediating distinct functions also need to be further discovered. The single-base, high-resolution and high-throughput sequencing technology for detecting m^6^A methylation also needs to be improved. Regulatory mechanisms and detailed biological functions of m^6^A modification need to be further investigated.

**Abbreviations**

ALKBH5: AlkB homolog 5; METTL3: methyltransferase-like protein 3; m^6^A: N6-methyladenosine; FTO: fat-mass and obesity-associated protein; RRE: Rev response element; R-2HG: R-2-hydroxyglutarate; WTAP: Wilms Tumor 1 Associated Protein; YTH: YTS21-B homology; 3’UTRs: 3’ untranslated regions.

**Acknowledgments**

This work was supported by the National Natural Science Foundation of China (No. 81872080, 81572349), Jiangsu Provincial Medical Talent (ZDRCA 2016055), the Science and Technology Department of Jiangsu Province (BK20181148), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) and the 333 high-level talents of Jiangsu Province (BRA2019083).

**Competing Interests**

The authors have declared that no competing interest exists.

**References**

1. Huang H, Weng H, Chen J. The Biogenesis and Precise Control of RNA m(6)A Methylation. Trends in genetics : TIG. 2020; 36: 44-52.
2. Huang J, Yin P. Structural Insights into N(6)-methyladenosine (m(6)A) Modification in the Transcriptome. Genomics, proteomics & bioinformatics. 2018; 16: 85-98.
3. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012; 485: 201-6.
4. Akchika S, Hirano S, Shichino Y, Suzuki T, Nishimasa H, Ishitani R, et al. Cap-specific terminal N (6)-methylolation of RNA by an RNA polymerase II-associated methyltransferase. Science. 2019; 363.
5. Fitzsimmons CM, Batista FJ. It's complicated m(6)A-dependent regulation of gene expression in cancer. Biochimica et biophysica acta Gene regulatory mechanisms. 2019; 1862: 382-93.
6. Fu Y, Jia G, Pang X, Wang RN, Wang X, Li CJ, et al. FTO-mediated modification of N(6)-hydroxymethyladenosine and N(6)-formyladenosine in mammalian RNA. Nature communications. 2013; 4: 1798.
7. Zheng G, Dahl JA, Niu Y, Fedorosak P, Huang CM, Li CJ, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Molecular cell. 2013; 49: 18-29.
8. Liao S, Sun H, Xu C. YTH Domain: A Family of N(6)-methyladenosine (m(6)A) Readers. Genomics, proteomics & bioinformatics. 2018; 16: 99-107.
9. Balacco DL, Soller M. The m(6)A Writer: Rise of a Machine for Growing Tasks. Biochemistry. 2019; 58: 363-78.
10. Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, et al. N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell. 2015; 161: 1388-99.
11. Liang Y, Zhan G, Chang KJ, Yang YP, Wang L, Lin J, et al. The roles of m6A RNA modifiers in human cancer. Journal of the Chinese Medical Association : JCMA. 2020; 83: 221-6.
12. Roundtree IA, He C. Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing. Trends in genetics : TIG. 2016; 32: 320-1.
13. Liu N, Dai Q, Zheng C, He C, Parisien M, Pan T. Non-m6A-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015; 518: 560-4.
14. Hsu PJ, He C. High-Resolution Mapping of N (6)-Methyladenosine Using m(6)A Crosslinking Immunoprecipitation Sequencing (m(6)A-CLIP-seq). Methods in molecular biology. 2019; 1987: 69-78.
15. Hsu PJ, He C. Identifying the m(6)A Methylome by Affinity Purification and Sequencing. Methods in molecular biology. 2018; 1649: 49-57.
16. Wang Z, Tang K, Zhang D, Wan Y, Wen Y, Lu Q, et al. High-throughput m6A-seq reveals RNA m6A methylation patterns in the chloroplast and mitochondria transcriptomes of Arabidopsis thaliana. Plos one. 2017; 12: e0185612.
17. Meyer KD, Saletore Y, Zumbo P, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. Cell. 2012; 149: 1635-46.
18. Grozhih AV, Linder B, Olarerin-George AO, Jaffrey SR. Mapping m6A at Individual-Nucleotide Resolution Using Crosslinking and Immunoprecipitation (mCLIP). Methods in molecular biology. 2017; 1562: 55-79.
19. Linder B, Grozhih AV, Olarerin-George AO, Meydan C, Mason CE, Jaffrey SR. Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nature methods. 2015; 12: 767-76.
20. Chen K, Lu Z, Wang X, Fu Y, Luo CZ, Liu N, et al. High-resolution N(6)-methyladenosine (m(6)A) A map using photo-crosslinking-assisted m(6)A sequencing. Angewandte Chemie. 2015; 54: 1587-90.
21. Ke S, Aleenu EA, Metters C, Gantman EC, Fak JJ, Mele A, et al. A majority of m(6)A resides in the last exons, which confers potential for 3' UTR regulation. Genes & development. 2015; 29: 2037-53.
22. Molinie B, Wang J, Lim KS, Hillebrand R, Lu ZX, Vanden Wijngaerde N, et al. m6A(LAI)-seq reveals the census and complexity of the m(6)A transcriptome. Nature methods. 2016; 13: 692-8.
23. Liu N, Pan T. Probing RNA Modification Status at Single-Nucleotide Resolution. Methods in Enzymology. 2015; 674-82.
24. Liu N, Parisien M, Dai Q, Zheng G, He C, Pan T. Probing N6-methyladenosine RNA modification status at single nucleotide resolution in mRNA and long noncoding RNA. Plos. 2013; 19: 1848-56.
25. Rau K, Rosner L, Rentmeister A. Sequence-specific m(6)A demethylation in mouse oocyte development. PLoS genetics. 2018; 14: e1007412.
26. Pontier D, Picart C, El Baidouri M, Roudier F, Wang Y, Vierkotten J, et al. m6A reader YTHDC1 regulates alternative polyadenylation and splicing. Nature. 2018; 555: 461-4.
27. Pontier D, Picart C, El Baidouri M, Roudier F, Lu Z, Vierkotten J, et al. The m(6)A reader YTHDC1 regulates alternative polyadenylation and splicing. Nature. 2018; 555: 461-4.
28. Grozhik AV, Linder B, Olarerin-George AO, Jaffrey SR. Mapping m6A at Individual-Nucleotide Resolution Using Crosslinking and Immunoprecipitation (mCLIP). Methods in molecular biology. 2017; 1562: 55-79.
29. Linder B, Grozhik AV, Olarerin-George AO, Meydan C, Mason CE, Jaffrey SR. Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nature methods. 2015; 12: 767-76.
30. Chen K, Lu Z, Wang X, Fu Y, Luo CZ, Liu N, et al. High-resolution N(6)-methyladenosine (m(6)A) A map using photo-crosslinking-assisted m(6)A sequencing. Angewandte Chemie. 2015; 54: 1587-90.
31. Ke S, Aleenu EA, Metters C, Gantman EC, Fak JJ, Mele A, et al. A majority of m(6)A resides in the last exons, which confers potential for 3' UTR regulation. Genes & development. 2015; 29: 2037-53.
32. Molinie B, Wang J, Lim KS, Hillebrand R, Lu ZX, Vanden Wijngaerde N, et al. m6A(LAI)-seq reveals the census and complexity of the m(6)A transcriptome. Nature methods. 2016; 13: 692-8.
33. Liu N, Pan T. Probing RNA Modification Status at Single-Nucleotide Resolution in Total RNA. Methods in enzymology. 2015; 560: 149-69.
34. Li GQ, Liu Z, Shen HB, Yu DJ. TargetM6A: Identifying N(6)-Methyladenosine Sites From RNA Sequences via Position-Specific Nucleotide Propensities and a Hidden Markov Model. BioMed research international. 2015; 2015: 852070.
35. Lin S, Choe J, Du P, Tribusman R, Gregory R. The m(6)A Methytransferase METTL3 Promotes Translation in Human Cancer Cells. Molecular cell. 2016; 62: 335-45.
36. Choe J, Lin S, Zhang W, Liu Q, Wang L, Ramirez-Moya J, et al. mRNA circularization by METTL3-eIF3F enhances translation and promotes oncogenesis. Nature. 2018; 561: 556-60.
37. Barbieri I, Tzelipis K, Pandalis I, Shi J, Millan-Zambrano G, Robson SC, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control. Nature. 2017; 552: 126-31.
38. Taketo K, Konno M, Asai A, Koseki J, Toratani M, Sato T, et al. The epitranscriptome m6A reader METTL13 regulates chemosensitivity and shows potential as a new therapeutic target. Molecular & cellular biochemistry. 2019; 450: 1378-88.
39. Ping XL, Sun BF, Wang L, Xiao W, Yang X, Wang WJ, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell research. 2014; 24: 177-89.
40. Xu K, Yang Y, Feng GH, Sun BF, Chen JQ, Li YF, et al. Mettl3-mediated m(6)A regulates spermatogenic differentiation and meiosis initiation. Cell research. 2017; 27: 1100-14.
41. Zhao X, Yang Y, Sun BF, Shi Y, Yang X, Xiao W, et al. FTO-dependent demethylation of N6-methylated RNA regulates m6A splicing and is required for adipogenesis. Cell research. 2014; 24: 1403-19.
42. Mehnk BM. Milk: an epigenetic amplifier of FTO-mediated transcription? Implications for Western diseases. Journal of translational medicine. 2015; 13: 388.
43. Nettersheim D, Berger D, Jostes S, Kristiansen G, Lochnit G, Schorle H. N6-Methyladenosine detected in RNA of testicular germ cell tumors is controlled by METTL3, ALKBH5, YTHDC1/F1/F2, and HNRNPC as writers, readers, and erasers. Andrology. 2019; 7: 408-506.
44. Zhou KI, Shi H, Liu R, Wyler AC, Matsuzek S, Pan JN, et al. Regulation of Co-transcriptional Pre-mRNA Splicing by m6A through the Low-Complexity Protein InRNP. Molecular cell. 2019; 76(6): 70-83.
45. Pontier D, Picart C, El Baidouri M, Roudier F, Tu L, Lahmy S, et al. The m(6)A pathway protects the transcriptome integrity by restricting RNA chimera formation in plants. Life science alliance. 2019; 2.
93. Tirumuru N, Zhao BS, Lu W, Zhao Y, Chen N, et al. m(6)A methylation modulates adiogenes is through JAK2-STAT3/C/EBPβ signaling. Biochimica et biophysica acta Gene regulatory mechanisms. 2019; 1862: 7965-78.

94. Lu W, Tirumuru N, St Gelais C, Koneru PC, Liu C, Kvaratskhelia M, et al. N(6)-Methyladenosine-binding proteins suppress HIV-1 infectivity and viral production. The Journal of biological chemistry. 2018; 293: 12992-3005.

95. Kennedy EM, Bajzer HP, Korenati AV, Kang D, Choshal D, Marshall JB, et al. Posttranscriptional m(6)A Editing of HIV-1 mRNAs Enhances Viral Gene Expression. Cell host & microbe. 2016; 19: 675-85.

96. Bader JP, Brown NR, Chiang BP, Kantoni GL, 3-Dazaadenosine, an inhibitor of an N6-adenosine hydroxymethylase, inhibits reproduction of Rous sarcoma virus and transformation of chick embryo cells. Virology. 1979; 84: 494-505.

97. Chiang PK. Biological effects of inhibitors of S-adenosylhomocysteine hydroxylase. Pharmacology & therapeutics. 1996; 77: 115-34.

98. Li, Bichang G, Zhao BS, Wu Y, Lu Z, Qin Y, He C, et al. Dynamics of Human and Viral RNA Methylation during Zika Virus Infection. Cell host & microbe. 2016; 20: 666-73.

99. Gokhale NS, McIntyre ABR, McFadden MJ, Roder AE, Kennedy EM, Gandra JA, et al. N6-Methyladenosine in Flaviviridae Viral RNA Genomes Regulates Infection. Cell host & microbe. 2016; 20: 654-65.

100. Tan B, Liu H, Zhang S, da Silva SR, Zhang L, Meng J, et al. Viral and cellular N(6)-methyladenosine and N(2)-O-dimethyladenosine epitranscripts in the HIV life cycle. Nature microbiology. 2018; 3: 10-20.

101. Zhong W, Wang H, Herndier B, Garani D. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93: 4910-4.

102. Imada H, Khan M, Gokhale NS, McIntyre ABR, Kim GW, Jiang JY, et al. N6-methyladenosine modification of hepatitis B virus RNA differentially regulates the viral life cycle. Proceedings of the National Academy of Sciences of the United States of America. 2018; 115: 8293-9.

103. Zhang C, Wu J, Gao X, Zhuang S, Jeffrey SR, Que SB. Dynamic m(6)A mRNA methylation directs translational control of heat shock response. Nature. 2015; 526: 591-6.

104. Yang X, Lauret B, Hsueh CH, Nachtigaele S, Lu Z, Zheng W, et al. m(6)A RNA methylation regulates the ultraviolet-induced DNA damage response. Nature. 2015; 523: 573-6.

105. Ries RJ, Zaccara S, Klein P, Olererin-George A, Namkoong S, Pickering BF, et al. m(6)A enhances the phase separation potential of mRNA. Nature. 2019; 571: 428-8.

106. Gao Y, Pei G, Li D, Li R, Shao Y, Zhang QC, et al. Multivalent m(6)A motifs promote phase separation of YTHDF proteins. Cell research. 2019; 29: 767-9.

107. Li HB, Teng J, Zhu S, Batista PJ, Duffy EE, Zhao J, et al. m(6)A mRNA methylation controls T cell development by targeting the IL-7/STAT5/SCOS pathways. Nature. 2017; 548: 338-42.

108. Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTIDFI in dendritic cells. Nature. 2019; 566: 270-4.

109. Zhang C, Fu J, Zhou Y. A Review in Research Progress Concerning m6A Methylation and Inflammation. Frontiers in immunology. 2019; 10: 922.

110. Batista PJ, Molinie B, Wang J, Qu K, Zhang J, Li L, et al. m(6)A RNA methylation regulates cell fate transition in mammalian embryonic stem cells. Cell stem cell. 2014; 15: 707-19.

111. Zhang C, Chen Y, Sun B, Wang L, Yang Y, Ma D, et al. m(6)A modulates haematopoietic stem and progenitor cell specification. Nature. 2017; 549: 490-6.

112. Lin Z, Hsu PJ, Xing X, Fang J, Lu Z, Zhou Q, et al. Mettl3-/Mettl14-mediated N6-methyladenosine modification controls cell fate transition in mammalian embryonic stem cells. Cell stem cell. 2014; 15: 707-19.

113. Zhang C, Chen Y, Sun B, Wang L, Yang Y, Ma D, et al. m(6)A modulates haematopoietic stem and progenitor cell specification. Nature. 2017; 549: 490-6.

114. Lin Z, Hsu PJ, Xing X, Fang J, Lu Z, Zhou Q, et al. Mettl3-/Mettl14-mediated N6-methyladenosine modification controls cell fate transition in mammalian embryonic stem cells. Cell stem cell. 2014; 15: 707-19.

115. Zhang C, Chen Y, Sun B, Wang L, Yang Y, Ma D, et al. m(6)A modulates haematopoietic stem and progenitor cell specification. Nature. 2017; 549: 490-6.

116. Lin Z, Hsu PJ, Xing X, Fang J, Lu Z, Zhou Q, et al. Mettl3-/Mettl14-mediated N6-methyladenosine modification controls cell fate transition in mammalian embryonic stem cells. Cell stem cell. 2014; 15: 707-19.

117. Zhang C, Chen Y, Sun B, Wang L, Yang Y, Ma D, et al. m(6)A modulates haematopoietic stem and progenitor cell specification. Nature. 2017; 549: 490-6.

118. Chang M, Lv H, Ma C, He X, Zhao S, et al. TFO Plays an Oncogenic Role in Breast Cancer Stem Cells Through the ULK1/AMPK Pathway. Cancer research. 2016; 76: E2047-E30.

119. Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, et al. FTO Plays an Oncogenic Role in Breast Cancer Stem Cells by Regulating Epithelial-mesenchymal transition. Nature communications. 2019; 10: 3417.

120. Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, et al. FTO Plays an Oncogenic Role in Breast Cancer Stem Cells by Regulating Epithelial-mesenchymal transition. Nature communications. 2019; 10: 3417.
Prefrontal Cortex Is Associated with Memory Processes in Mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2016; 36: 6771-7.

122. Li J, Yang X, Qi Z, Sang Y, Liu Y, Xu B, et al. The role of mRNA m(6)A methylation in the nervous system. Cell & bioscience. 2018; 9: 66.

123. Wang CX, Cui GS, Liu X, Xu K, Wang M, Zhang X, et al. METTL3-mediated m6A modification is required for cerebellar development. PLoS biology. 2018; 16: e2004880.

124. Zhang Z, Wang M, Xie D, Huang Z, Zhang L, Yang Y, et al. METTL3-mediated N(6)-methyladenosine mRNA modification enhances long-term memory consolidation. Cell research. 2018; 28: 1050-61.

125. Shi H, Zhang X, Weng YL, Lu Z, Liu Y, Lu Z, et al. m(6)A facilitates hippocampus-dependent learning and memory through YTHDF1. Nature. 2018; 563: 249-53.

126. Lin X, Chai G, Wu Y, Li J, Chen F, Liu J, et al. RNA m(6)A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail. Nature communications. 2019; 10: 2865.

127. Rong ZX, Li Z, He JJ, Liu LY, Ren XX, Gao J, et al. Downregulation of Fat Mass and Obesity Associated (FTO) Promotes the Progression of Intrahepatic Cholangiocarcinoma. Frontiers in oncology. 2019; 9: 369.

128. Panneerdoss S, Eedunuri VK, Yadav P, Timilsina S, Rajamanickam S, Viswanadhapalli S, et al. Cross-talk among writers, readers, and erasers of m(6)A regulates cancer growth and progression. Science advances. 2018; 4: eaar8263.

129. Liu Y, Wang R, Zhang L, Li J, Lou K, Shi B. The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway. Oncology letters. 2017; 13: 4685-90.

130. Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, et al. N(6)-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance. Cancer research. 2019; 79: 2812-20.

131. Su R, Dong L, Li C, Nachtgeraale S, Wunderlich M, Qing Y, et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling. Cell. 2018; 172(e23): 90-105.

132. Kehat I, Davis J, Tiburcy M, Accornero F, Saha-El-Leil MK, Maillet M, et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circulation research. 2011; 108: 176-83.

133. Song H, Feng X, Zhang H, Luo Y, Huang J, Lin M, et al. METTL3 and ALKBH5 oppositely regulate m(6)A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes. Autophagy. 2019; 15: 1419-37.

134. Gustavsson J, Mehlig K, Leander K, Lissner L, Björck L, Rosengren A, et al. FTO genotype, physical activity, and coronary heart disease risk in Swedish men and women. Circulation Cardiovascular genetics. 2014; 7: 171-7.

135. Mathiyalagan P, Adamiak M, Mayourian J, Sassi Y, Liang Y, Agarwal N, et al. FTO-Dependent N(6)-Methyladenosine Regulates Cardiac Function During Remodeling and Repair. Circulation. 2019; 139: 518-32.